DP,
IMO, an extremely well thought out and well composed post, both in a reflexive and forward looking manner. If cool heads prevail and sensible decisions are made PBT2 may well yet get to market for both indications (HD and AD). The existing body of positive evidence is far too great for the drug to be considered a failure based solely on the results of this trial.
The investment potential is still there, but the question as always is, 'will it be realised'? That is for each investor to decide as the further story unfolds.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $109.5M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $197.9K | 16.36M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 28859638 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 495925 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |